USD FUNDING CONDITIONS AND XCCY DEVELOPMENTS

ECB MMCG JUNE 16TH 2020

PATRICK CHAUVET

CORPORATE & INSTITUTIONAL BANKING GLOBAL MARKETS



The bank for a changing world

Summary

USD money market

The Fed has introduced a large number of crisis support mechanisms including direct Fed intervention, support of bank-intermediated activity and targeted measures.

Acute dash to cash in March with strong inflows into govt-only money market funds outflows from prime funds could be reversed.

Fed balance sheet assets and liabilities exploded in March with repo operation increases, Fed QE and a plethora of Fed liquidity programmes.

Excess liquidity chasing quality collateral assets compressed frontend USD liquidity spreads (including fed funds, SOFR and T-bills), but not 3m Libor at a first stage as 90-day CP issuance took more than 1 month to resume.

3m Libor/OIS rose to 135bp with wider 90d financial CP/OIS, despite 5y financial CDS tightening and other Fed funding support. As financial CP issuance slowed and shortened sharply, several Libor Panel members certainly had to contribute 3m Libor by observing FX swap prices and other proxies / indicators, using expert judgement only for some time.

This created an unprecedented dislocation of the BOR BOR XCCY curve as OIS OIS XCCY curves came back while USD Libor stayed elevated.

Xccy basis

The FED USD vs collateral facility at 25 bp cost was a major action in favour of the "Eurodollar" liquidity and the global banking system functioning

The quarter end turn was also a clear relief for funding markets as it had clearly intensified the widening in the front-end xccy basis in the second half of March. Q1 typically sees the second-largest widening, after the Q4 turn, amid the reduced availability of USD funding.

Banks had more appetite for the 3-month USD supply operation, but the 7-day operation offered on a daily basis clearly came as a very welcome backstop and dampened the volatility in the xccy basis.

From there the 3mth OISOIS EURUSD basis tightened back slowly but surely to the -40bp and then to the -25 bp level (of the facility)

Propagation of USD scarcity impact to longer tenors of the XCCY curve was clearly stopped by the FED facility, combined with QE, Credit and fiscal support.

Global Credit and fiscal support were key in keeping opened capital markets and allowed record long term issuance could go through in USD and EUR notably, fuelling the liquidity in XCCY markets and anchoring the long part of the curve. Best rated European Corporate and SSA issuance in USD notably helped.

As the 84 days operations done in March and April expire, amid the coming June Quarter end, TGA accounts balance increase, but with record excess liquidity in USD, market looks confident that it will be able to deal with some reduction of the facility usage as its backstop dimension remains present.



USD money market

US money market: Most of the Stress is gone (data to June 4th)



Fig. 2: It looked like 2008 all over again



US Federal Reserve: what happened

- 15 March: Central banks around the globe reinstated provisions of USD liquidity via 3-month USD FX swap lines on a weekly basis, at a reduced cost of OIS+25bp, to restore access to USD funding.
- 17 March: The Fed's Commercial Paper Funding Facility (CPFF) was announced. However, the initial price, OIS+200bp for 3m CPs, was disappointing.

One could argue that to some extent this triggered a further cheapening of commercial paper toward that price. Lowering it was therefore the most likely option.

- **18 March:** The Fed established the Money Market Mutual Fund Liquidity Facility (MMLF), a programme that began on 23 March.
- **20 March:** Since this date, 7-day USD operations have been offered on a daily basis (they were previously offered weekly).
- 23 March: The Fed lowered the cost on the CPFF to OIS+110bp for CPs rated at least A1/P1, a welcome but necessary development, and to OIS+200bp for CPs rated A2/P2. It also clarified that eligible issuers included US branches of foreign banks.

At the same time, the Fed announced a set of targeted measures aiming to tackle the problem at the source: corporates and SMEs. These measures came on top of the announced MMLF that addresses spillovers to money market funds.

- 31 March: Fed announces temporary FIMA repo facility allowing overseas central banks to enter in repo agreements exchanging their US Treasury for US dollars. Active from 6 April and will continue for at least six months.
- Limited direct buying of commercial paper by the Fed combined with other measures managed to bring back market to function, and slowly recover from the end of March, as we see in next slides

US money market: Dash to cash, excess liquidity chasing quality collateral



Jpe	Ao in (obii)	Twong	nn e ng	onnong	onnong	iy or
e	758	7	59	-41	-19	96
& Repo	1,213	-21	-29	414	417	541
ency	2,662	-22	-9	698	781	974
xable	4,633	-38	21	1071	1180	161

AUM Change (%)							
1wChg	1m C hg	3m chg	6m chg	1y chg			
1%	8%	- 5%	-2%	15%			
-2%	-2%	52%	52%	81%			
-1%	0%	38%	42%	58%			
-1%	0%	30%	34%	53%			

Sources: ICI, Bloomberg, Macrobond, BNP Paribas

Treasury & Govt/Ag Total Ta:

- Money market funds showed strong flight to cash and quality pressures in March:
 - First,\$150bn outflows from prime funds (-20%) with shortening in WAMs. Huge inflow into govt-only funds (\$750bn, +30%).
- Fed balance sheet assets and liabilities exploded in March with repo, Fed QE and plethora of Fed liquidity programmes.
 - Assets Repo (+\$157bn), UST (+\$800bn), MBS (+\$150bn), CB \$ swaps (+206bn), PDCF (+\$28bn), MMFL (+\$31bn).
 - Liabilities Currency in circulation/cash (+\$72bn), Foreign RRP (+\$44bn), RRP (+\$95bn), Other deposits (+\$203bn), Reserves (+\$800bn).
- Compression in front-end liquidity spreads: Fed funds flat to IOER, SOFR went 9bp through fed funds, T-bills yields went negative for a while
 - Risk was that SOFR (overnight) print negative with volume of USTs trading with negative repo rates amidst heavy Fed quantitative easing.

US CPFF 2.0: more of a backstop and part of a global answer





Sources: Federal Reserve, Bloomberg, BNP Paribas

- US commercial paper market remained broken for all April despite the XCCY program and the FED starting to buy CP mid April
 - Volume of 90-day CP (and even 30d) issuance (financials) had collapsed, making short-term bank funding costs volatile and difficult to observe.
 - There were signs of very short-term rolling financing for A2/P2 (non-fin) issuers amidst ongoing credit crunch.
- Design of CPF 2.0 had its flaws, but the Fed has overall been very responsive in this liquidity crisis management
 - Delay: Implementation took some time
 - Accessibility: Lack of access to foreign banking parents limits scope and efficacy of reducing USD funding needs.
 - Credit spectrum: Very limited support for A2 borrowers (hardest hit?) at punitive credit spreads.
- 3m Libor/OIS rose to 135bp, less than 90d financial CP/OIS, with 5y financial CDS tightening thanks to other forms of Fed / CBs funding support
- Deep and diverse Fed crisis support mechanisms including direct Fed intervention and support of bank-intermediated activity. New Fed repo facility from 6th April!
 - Higher bank reserves with QE, credit purchases (PMCCF, SMCCF) and USD liquidity (swap/repo lines, CPFF, PDCF and MMLF, FIMA repo facility) allowed to bring back down the price of liquidity and avoid a full bank credit crisis by improving availability of USDs and reducing need to sell USTs.
 - It was also clear during the end of March that the announcements of huge US (and later worldwide) Fiscal packages helped to slow and revert the fears of a Banking system collapse amid unprecedented Corporate and employment crisis, contributing to a normalisation of the availability of USD for non US too

Sources: Federal Reserve, Bloomberg, BNP Paribas



Xccy: BORBOR versus OISOIS

- A surge in the cost of unsecured USD funding (wider \$OIS/BOR) is typically accompanied by a surge in the cost of 'secured' USD funding (secured by the exchange of notionals, collateral and measured by the wider OIS/OIS xccy basis).
- While the central bank 3-month USD funding operation initially had a mixed impact on the xccy basis, the 7-day operation switched from weekly to daily on 20 March, leading to a stabilisation in the xccy basis.

Front-end OIS/OIS basis versus longer BOR/BOR tenors

- OIS/OIS xccy the standard measure at the front end measures the true cost of funding USD via xccy swaps.
- BOR/BOR xccy the standard measure in 1y+ tenors is polluted by OIS/BOR in both currencies.
- As the \$OIS/BOR spread widened significantly, much more than in EUR, the overall impact from OIS/BOR has been that of a tightening (less negative) impact on the BOR/BOR xccy basis, as it partially offsets the widening in the OIS/OIS xccy basis.

20 -20 10 -10 0 0 10 -10 -20 20 -30 30 -40 40 €OIS/BOR 50 BOR/BOR xecy = OIS/OIS xccy + \$OIS/E -50 €OIS/BOR - \$OIS/BOR (bp, rhs) -60 60 EUR/USD 1y BOR/BOR basis (bp) -70 70 EUR/USD 1y OIS/OIS (bp) -80 80 \$ois/bor (bp, rhs) 2019 2020

Sources: BNP Paribas

Fig. 1: From OIS/OIS to BOR/BOR xccy basis

Xccy: OIS OIS historical, a very sudden spike quickly contained



Sources: BNP Paribas

Fig. 2: EUR market turned on the 16th, USDJPY on the 20th

1mth and 3mth OIS OIS XCCY USDJPY vs EURUSD

1mth OIS OIS XCCY in USDJPY move was highest since 2008 it was more contained in EURUSD

- The strength of the turn in JPY was certainly part of the explanation of that difference
- Going into FED Facility rolls, the market is not showing any significant tension, despite 1mth moving wider than 3mth (turn again?)





Xccy: Q1 end played a role in worsening the situation in March

Quarter turn: reduced availability of USD

 According to internal data, the Q1 turn typically sees the second-largest widening, after the Q4 turn.

Fig. 1: EUR/USD quarter turn: 3-month average into the turn

(in bp)	2016	2017	2018	2019	2020	Avg
Q1	-276	-519	-266	-168	-233	-307
Q2	-463	-251	-317	-125		-289
Q3	-258	-179	-128	-387		-238
Q4	-435	-574	-1361	-946		-829
Avg	-358	-381	-518	-407		

- The front-end basis typically widens into the quarter end due to the reduced availability of USD around reporting dates.
- The turn is particularly acute in JPY/USD basis, as 31 March marks the end of the fiscal year in Japan.



Fig. 3: Q2 2020 turn: on a widening trajectory



Fig. 2: Q1 2020 turn across currencies

Xccy: OIS OIS historical, an overall well contained impact?



Fig. 1: 2mth in 1mth forward OISOIS basis showing much less impact than 2008

2mth in 1mth forward allows to remove / smooth partly the Quarter end / Year end impacts,

1y1y shows the impact for longer maturities

- 2mth in 1mth EURUSD level didn't go beyond other crisis levels (2008 excluded)
- Both EURUSD and USDJPY 1mth2mth widened much less than in 2008
- 1y1y in EUR remained well below last decade tension levels. Even USDJPY move was more contained
- FED and other CBs have succeeded in stopping the process before it became a banking system liquidity and credit crisis





Xccy: FED facility usage

Fig. 1: Japan and Europe main users, >90% in 84d







Fig. 2: 50% of outstanding to mature by June 18th and 90% by mid July



Sources: BNP Paribas



	Amounts (\$bn)			Percentage		
FED USD Swap Lines to Central Banks	7 days	84 days	All Maturities	7 days	84 days	All Maturities
Bank of Japan	0,0	189,0	189,0	0%	58%	58%
European Central Bank	0,0	69,0	69,0	0%	21%	21%
Bank of England	0,0	13,4	13,4	0%	4%	4%
Bank of Korea	0,0	18,8	18,8	0%	6%	6%
Swiss National Bank	0,0	10,5	10,5	0%	3%	3%
Banco de Mexico	0,0	6,6	6,6	0%	2%	2%
Monetary Authority of Singapore	0,2	9,3	9,6	100%	3%	3%
Norges Bank	0,0	5,4	5,4	0%	2%	2%
Reserve Bank of Australia	0,0	1,2	1,2	0%	0%	0%
Danmarks Nationalbank	0,0	4,3	4,3	0%	1%	1%
Total	0,2	327,5	327,7	0%	100%	100%

Sources: BNP Paribas

DISCLAIMER

Legal Notice: This document/communication may contain "Research" as defined under MiFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MiFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MiFID II unbundling rules and have signed up to a BNP Paribas Global Markets Research package, or (ii) for firms that are out of scope of the MiFID II unbundling rules and therefore are not required to pay for Research under MiFID II. Please note that it is your firm's responsibility to ensure that you do not view or use any Research in this document if your firm has not signed up to a BNP Paribas Global Markets Research package, unless your firm is out of scope of the MiFID II unbundling rules. This document may also be regarded as a minor non-monetary benefit (MNMB) and it is your firm's responsibility to consider its own regulatory obligations in relation to inducements and accepting MNMBs.

This document is CONFIDENTIAL AND FOR DISCUSSION PURPOSES ONLY; it constitutes a marketing communication and has been prepared by a Sales and Marketing function within BNP Paribas and/or its subsidiaries or affiliates (collectively "we" or "BNP Paribas"). As a confidential document it is submitted to selected recipients only and it may not be made available (in whole or in part) to any other person without BNP Paribas' written consent.

This document is not a recommendation to engage in any action, does not constitute or form any part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. To the extent that any transaction is subsequently entered into between the recipient and BNP Paribas, such transaction will be entered into upon such terms as may be agreed by the parties in the relevant documentation. The information contained in this document has been obtained from sources believed to be reliable, but there is no guarantee of the accuracy, completeness or suitability for any particular purpose of such information or that such information has been independently verified by BNP Paribas or by any person. None of BNP Paribas, its members, directors, officers, agents or employees accepts any responsibility or liability whatsoever or makes any representation or warranty, express or implied, as to the accuracy or completeness of the information, or any opinions based thereon, contained in this document and it should not be used in place of professional advice. Additional information may be provided on request, at our discretion. Any scenarios, assumptions, historical or simulated performances, indicative prices or examples of potential transactions or returns are included for illustrative purposes only. Past performance is not indicative of future results. Investors may get back less than they invested. BNP Paribas gives no assurance that any favourable scenarios described are likely to happen, that it is possible to trade on the terms described herein or that any potential returns illustrated can be achieved. This document is current as at the date of its production and BNP Paribas is under no obligation to update or keep current the information herein. In providing this document, BNP Paribas offers no investment, financial, legal, tax or any other type of advice to, and has no fiduciary duty towards, recipients. Certain strategies and/or potential transactions discussed in this document may involve the use of derivatives which may be complex in nature and may give rise to substantial risks, including the risk of total or partial loss of any investment or losses without limitation and which should only be undertaken by those with the requisite knowledge and experience. BNP Paribas makes no representation and gives no warranty as to the results to be obtained from any investment, strategy or transaction, or as to whether any strategy, security or transaction described herein may be suitable for recipients' financial needs, circumstances or requirements. Recipients must make their own assessment of strategies, securities and/or potential transactions detailed herein, using such professional advisors as they deem appropriate. BNP Paribas accepts no liability for any direct or consequential losses arising from any action taken in connection with or reliance on the information contained in this document even where advised of the possibility of such losses.

As an investment bank with a wide range of activities BNP Paribas may face conflicts of interest and you should be aware that BNP Paribas and/or any of its affiliates may be long or short, for their own account or as agent, in investments, transactions or strategies referred to in this document or related products before the material is published to clients and that it may engage in transactions in a manner inconsistent with the views expressed in this document, either for their own account or for the account of their clients. Additionally, BNP Paribas may have acted as an investment banker or may have provided significant advice or investment services to companies or in relation to investments mentioned in this document. The information in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction where (a) the distribution or use of such information would be contrary to law or regulations, or (b) BNP Paribas or a BNP Paribas affiliate would become subject to new or additional legal or regulatory requirements. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly.

This document is intended for, and is directed at, (a) Professional Clients and Eligible Counterparties as defined by the European Union Markets in Financial Instruments Directive ("MiFID"), and (b) where relevant, persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and at other persons to whom it may lawfully be communicated (together "Relevant Persons"). Any investment or investment activity to which this document relates is available only to and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or its content.

This document is being communicated by BNP Paribas London Branch, 10 Harewood Avenue, London NW1 6AA; tel: +44 (0)20 7595 2000; fax: +44 (0)20 7595 2555 (www.bnpparibas.com). Incorporated in France with Limited Liability. Registered Office: 16 boulevard des Italiens,75009 Paris, France. 662 042 449 RCS Paris. BNP Paribas London Branch is lead supervised by the European Central Bank (ECB) and the Autorité de Contrôle Prudentiel et de Résolution (ACPR). BNP Paribas London Branch is authorised by the ECB, the ACPR and the Prudential Regulation Authority and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority. Details about the extent of our authorisation and regulation by the Prudential Regulation by the Financial Conduct Authority are available from us on request. BNP Paribas London Branch is registered in England and Wales under no. FC13447. © BNP Paribas 2019. All rights reserved.

